July 28, 2017 / 10:40 AM / 2 years ago

BRIEF-ImmunoGen reports recent progress and second quarter 2017 operating results

July 28 (Reuters) - Immunogen Inc

* Q2 loss per share $0.10

* Q2 revenue $39 million versus $7.4 million

* Q2 revenue view $30.6 million — Thomson Reuters I/B/E/S

* Q2 earnings per share view $-0.16 — Thomson Reuters I/B/E/S

* Sees FY 2017 revenue $115 million to $120 million

* ImmunoGen Inc - ‍operating expenses remain unchanged and are expected to be between $175 million and $180 million for 2017​

* ImmunoGen - ‍expects current cash plus expected cash revenues from partners and collaborators will enable co to fund operations into second half of 2018​

* FY2017 revenue view $92.0 million — Thomson Reuters I/B/E/S

* ImmunoGen Inc - ‍cash and cash equivalents at December 31, 2017 are expected to be between $90 million and $95 million​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below